Addiction of High Dose of Benzodiazepine: Verona Detox Approach With Flumazenil

Overview

Journal Front Psychiatry

Specialty Psychiatry

Date 2022 Apr 18

PMID 35432044

Authors

Rebecca Casari

Antonio Metastasio

Lorenzo Zamboni

Martino Biasioli

Simone Campagnari

Fabio Lugoboni

Affiliations

Soon will be listed here.

Abstract

Introduction: Since the 1990s there has been evidence of the significant role Flumazenil (FLU) has in benzodiazepines (BZD) detoxes. The Verona Detox approach has been developed for high dose BZD and Z-drug detoxification via continuous subcutaneous infusion of FLU, a selective BZD receptor antagonist acting on the BZD subunit of the GABA-A receptor. Flumazenil is licensed in the United Kingdom and other countries to treat only BZD overdose although numerous studies have demonstrated its effectiveness in rapidly resetting GABA-A receptors, quickly reducing tolerance and dependence from BZD, and providing a safe and rapid detox from benzodiazepines.

Objective: The aim of this article is to provide all healthcare professional who are interested in BZD detoxification with an approach and clear practical information on how to administer FLU.

Method: In this article we outline the approach in detail, describing all medical and nursing procedures day by day. This detox treatment is indicated for patients abusing from at least 5 Defined Daily Dose (DDD) of BZDs or Z-drugs. The process lasts 7 days, and is conducted under medical supervision (daily reviews) and continuous nursing (24/7). During this period, 7mg of FLU is administered (1 mg/24) through an elastomeric pump, via continuous subcutaneous infusion.

Conclusion: To this day, the largest database of FLU detoxification was published by our group, showing how this treatment is safe, with very little side effects even in patients with significant medical comorbidities.

Citing Articles

High-dose benzodiazepine use and QTc interval prolongation, a latent class analysis study.

Zamboni L, Portoghese I, Casari R, Fusina F, Santin L, Lecca L Sci Rep. 2024; 14(1):155.

PMID: 38168538 PMC: 10762262. DOI: 10.1038/s41598-023-50489-3.

Benzodiazepines in sport, an underestimated problem: Recommendations for sports medicine physicians' practice.

Zandonai T, Peiro A, Fusina F, Lugoboni F, Zamboni L Front Psychiatry. 2023; 13:1066330.

PMID: 36620691 PMC: 9810623. DOI: 10.3389/fpsyt.2022.1066330.

Case Report: High doses of Zolpidem and QT interval lengthening: Is there a relationship? A case series.

Campagnari S, Zamboni L, Fusina F, Casari R, Lugoboni F Front Psychiatry. 2022; 13:1033061.

PMID: 36339861 PMC: 9632434. DOI: 10.3389/fpsyt.2022.1033061.

References

Lugoboni F, Gerra G, Tamburin S . Treatment of Benzodiazepine Dependence. N Engl J Med. 2017; 376(24):2399. DOI: 10.1056/NEJMc1705239. View

Janhsen K, Roser P, Hoffmann K . The problems of long-term treatment with benzodiazepines and related substances. Dtsch Arztebl Int. 2015; 112(1-2):1-7. PMC: 4318457. DOI: 10.3238/arztebl.2015.0001. View

Quaglio G, Faccini M, Victorri Vigneau C, Casari R, Mathewson S, Licata M . Megadose bromazepam and zolpidem dependence: two case reports of treatment with flumazenil and valproate. Subst Abus. 2012; 33(2):195-8. DOI: 10.1080/08897077.2011.638735. View

Hollister L, MOTZENBECKER F, DEGAN R . Withdrawal reactions from chlordiazepoxide ("Librium"). Psychopharmacologia. 1961; 2:63-8. DOI: 10.1007/BF00429621. View

Cloos J, Lim Cow C, Bocquet V . Benzodiazepine high-doses: The need for an accurate definition. Int J Methods Psychiatr Res. 2021; 30(4):e1888. PMC: 8633930. DOI: 10.1002/mpr.1888. View

Fang S, Chen C, Chang I, Chia-Hsuan Wu E, Chang C, Lin K . Predictors of the incidence and discontinuation of long-term use of benzodiazepines: a population-based study. Drug Alcohol Depend. 2009; 104(1-2):140-6. DOI: 10.1016/j.drugalcdep.2009.04.017. View

Webb C, Wanbon R, Otto E . Levetiracetam for Status Epilepticus in Adults: A Systematic Review. Can J Hosp Pharm. 2022; 75(1):46-53. PMC: 8677000. DOI: 10.4212/cjhp.v75i1.3254. View

Hood S, ONeil G, Hulse G . The role of flumazenil in the treatment of benzodiazepine dependence: physiological and psychological profiles. J Psychopharmacol. 2009; 23(4):401-9. DOI: 10.1177/0269881108100322. View

Soyka M . Treatment of Benzodiazepine Dependence. N Engl J Med. 2017; 376(12):1147-1157. DOI: 10.1056/NEJMra1611832. View

10.

Tamburin S, Faccini M, Casari R, Federico A, Morbioli L, Franchini E . Low risk of seizures with slow flumazenil infusion and routine anticonvulsant prophylaxis for high-dose benzodiazepine dependence. J Psychopharmacol. 2017; 31(10):1369-1373. DOI: 10.1177/0269881117714050. View

11.

Liebrenz M, Boesch L, Stohler R, Caflisch C . Benzodiazepine dependence: when abstinence is not an option. Addiction. 2010; 105(11):1877-8. DOI: 10.1111/j.1360-0443.2010.03177.x. View

12.

Lader M . Benzodiazepines revisited--will we ever learn?. Addiction. 2011; 106(12):2086-109. DOI: 10.1111/j.1360-0443.2011.03563.x. View

13.

Bialer M . Why are antiepileptic drugs used for nonepileptic conditions?. Epilepsia. 2012; 53 Suppl 7:26-33. DOI: 10.1111/j.1528-1167.2012.03712.x. View

14.

Gallo A, Hulse G . Pharmacological uses of flumazenil in benzodiazepine use disorders: a systematic review of limited data. J Psychopharmacol. 2021; 35(3):211-220. DOI: 10.1177/0269881120981390. View

15.

Echevarria M, Andrade Reis T, Ruffo Capatti G, Siciliano Soares V, da Silveira D, Fidalgo T . N-acetylcysteine for treating cocaine addiction - A systematic review. Psychiatry Res. 2017; 251:197-203. DOI: 10.1016/j.psychres.2017.02.024. View

16.

Petitjean S, Ladewig D, Meier C, Amrein R, Wiesbeck G . Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies. Int Clin Psychopharmacol. 2007; 22(5):292-8. DOI: 10.1097/YIC.0b013e328105e0f2. View

17.

Gerra G, Giucasto G, Zaimovic A, Fertonani G, Chittolini B, Avanzini P . Intravenous flumazenil following prolonged exposure to lormetazepam in humans: lack of precipitated withdrawal. Int Clin Psychopharmacol. 1996; 11(2):81-8. View

18.

Kelty E, Martyn V, ONeil G, Hulse G . Use of subcutaneous flumazenil preparations for the treatment of idiopathic hypersomnia: A case report. J Psychopharmacol. 2014; 28(7):703-6. DOI: 10.1177/0269881114523865. View

19.

Cloos J, Bocquet V, Rolland-Portal I, Koch P, Chouinard G . Hypnotics and Triazolobenzodiazepines--Best Predictors of High-Dose Benzodiazepine Use: Results from the Luxembourg National Health Insurance Registry. Psychother Psychosom. 2015; 84(5):273-83. DOI: 10.1159/000434755. View

20.

Jankovic S, Dostic M . Choice of antiepileptic drugs for the elderly: possible drug interactions and adverse effects. Expert Opin Drug Metab Toxicol. 2011; 8(1):81-91. DOI: 10.1517/17425255.2012.645535. View